observed in UC. Therefore, we evaluated the usefulness of DRI in UC patients with mild to moderate endoscopic severity.
Patients and methods

Patients
From March 2012 to April 2013, a total of 43 patients previously diagnosed with UC at the outpatient department of Keio University Hospital were enrolled in this study. All UC patients were diagnosed according to the criteria of the Research Committee on Inflammatory Bowel Disease in Japan [8] . Patients with fulminant disease were excluded because they required immediate intensive medical therapeutics, hospitalization, or surgery. This study was retrospectively conducted, and the clinical indices were prospectively collected during regular visits.
Dual-red imaging
This new imaging technology uses illumination at 3 wavelengths: 540 nm, 600 nm and 630 nm. With respect to the identification of blood vessels in the submucosal tissue, the 600-nm and 630-nm lights can penetrate the deeper tissue because the scattering properties of these lights are minimal. Furthermore, light absorption by blood vessels is much stronger at 600 nm than at 630 nm. Therefore, the intensity of light reflected by blood vessels at 630 nm is greater than that at 600 nm. This difference allows detection of blood vessels in the deeper tissue using the intensity balance of each wavelength of reflected light rather than white-light imaging (WLI) and DRI. The mechanism underlying how blood flow and bleeding can be more easily identified using DRI compared with conventional imaging methods is being actively studied.
Colonoscopy
Total ileocolonoscopies (ICS) were performed on all 43 patients. All patients were required to drink 2000 mL to 3000 mL of polyethylene glycol (Ajinomoto Farma, Co, Ltd, Tokyo, Japan) before the procedure. Pethidine hydrochloride (Tanabe-Mitsubishi, Tokyo, Japan) was administered immediately prior to ICS to reduce patient burden. All colonoscopy images were recorded on a digital versatile disc. Physicians could instantaneously switch from WLI to DRI by pressing a button on the control handle of the colonoscope. WLI and DRI recordings were taken in the ascending colons, sigmoid colons, and rectums of all 43 patients. To reduce the risk of bleeding caused by biopsies, we evaluated the severity of inflammation for only 3 colonic segments. In all cases, at each segment, the WLI was recorded first, and then the DRI was recorded at the same lesions. A total of 129 videos were collected, and 17 videos were excluded due to insufficient bowel cleaning. Finally, 112 videos (37 from the ascending colon, 35 from the sigmoid colon, 40 from the rectum) were collected to evaluate the endoscopic severity of inflammation using WLI and DRI.
Scoring the severity of inflammation
Five endoscopists independently evaluated the severity of mucosal inflammation using the Mayo endoscopic score [9] for the WLI videos of the 112 segments of the colon. One was an expert in diagnosis of UC (approximately 400 colonoscopies for UC annually), and the other 4 investigators were non-experts (50 cases annually). The endoscopic severity of inflammation seen using DRI was also evaluated using a novel DRI score. The Mayo score was classified as follows: below 0, normal; 1, erythema, decreased vascular pattern, mild friability; 2, marked erythema, absent vascular pattern, friability, erosion; 3, spontaneous bleeding, ulcerations. The DRI scores were classified as DRI 1, 2, 3, and 4. DRI1 was defined as a normal vascular pattern in both the superficial (brown) and deep (green) vessels. DRI2 was defined as the patchy or complete obliteration of the brown vessels with clear reorganization of the green vessels. DRI3 was defined as patchy obliteration of the green vessels, and DRI4 was defined as the complete obliteration of the green vessels. The overall severity was also assessed on a visual analogue scale (VAS). VAS scores ranged from 0 (completely normal) to 100 (most severe).
Histologic severity of inflammation was scored by a pathologist using the Geboes score [10] as follows: grade 0, structural and architectural changes; grade 1, chronic inflammatory infiltrate; grade 2, neutrophils and eosinophils in the lamina propria; grade 3, neutrophils in the epithelium; grade 4, crypt destruction; grade 5, erosions or ulceration. The pathologist was blinded to the clinical information.
Assessment of clinical prognosis in patients with various DRI scores
The usefulness of DRI scores for predicting clinical outcomes was assessed. Partial Mayo scores were recorded on the patients' medical charts at each visit to the clinic. Clinical remission was defined as a partial Mayo score ≤ 1. The rate of clinical recurrence was analyzed for patients with each DRI score (from DRI1 to DRI4). Clinical recurrence was defined as a partial Mayo score ≥ 3.
Data collection and statistical assessment
Our main endpoints in this study were as follows: 1) assessment of the correlation between the DRI score and the Mayo endoscopic score and between the DRI score and the histological grade, 2) inter-observer agreement on the DRI score and the Mayo endoscopic score, and 3) assessment of the correlation between the DRI score and the rate of recurrence in patients with clinical remission.
We evaluated the correlation between the DRI score, the Mayo endoscopic score and the histopathological grade using Spearman's rank correlation coefficient. To validate the DRI score, interobserver agreement between 2 endoscopists was examined, and the kappa value was calculated. Clinical information, such as age, gender, duration of disease, disease type (first attack, relapsing/remission or chronic continuous) and the use of medical treatments (at the time of the colonoscopy and at each visit to the clinic), was collected. Although we did not schedule visits to the clinic, most patients visited our hospital every 8 to 12 weeks.
In patients with clinical remission, the association between the DRI score and the time until clinical recurrence was assessed using the Kaplan-Meier method, and the difference be-tween the groups was analyzed using the log-rank test and the Breslow test. All P values are two-tailed, and P < 0.05 was considered statistically significant. All statistical analyses were performed using Statistical Package for the Social Sciences software version 22.0 (SPSS Inc., Chicago, IL).
Results
Patient characteristics at baseline
The clinical features of the patients and their medications for UC are listed in ▶ Table 1 . Forty-three patients with UC were included; of them, 36 (84 %) and 5 (12 %) were taking oral 5-aminosalicylates and thiopurine, respectively, whereas 7 patients did not take any medication for UC. The mean partial Mayo score of this cohort was 1.2. Serum CRP levels ranged from 0.01 to 1.35 mg/dL, and CRP levels were within the normal range (less than 0.35 mg/dL in our institution) in 84 % of patients.
Correlation between DRI score and VAS score for the severity of inflammation ▶ Fig. 1 indicates the typical findings for each DRI score in patients with UC. A total of 112 segments were assessed for the severity of inflammation using the Mayo endoscopic score, the DRI score and the VAS score. The mean DRI and VAS scores were 2.9 ± 1.2 (range: 1 -4) and 25.0 ± 18.1 (range 4.5 -65.5), respectively. The distribution of severity scores using the VAS (0 -100 points) with DRI is presented in ▶ Fig. 2 . The VAS score was significantly correlated with the DRI score (r = 0.957, P < 0.001). The median VAS score in patients scored as DRI1, 2, 3, and 4 was 6.5 (interquartile range, IQR = 2.6), 18.0 (IQR = 5.0), 35.0 (IQR = 7.0), and 52.5 (IQR = 8.3), respectively. Left-sided colitis 8
▶
Distal colitis 9
Proctitis 8
Type
Current treatment No medication 7
Oral 5-ASA 36
Topical 5-ASA 7
Topical steroid 2
Thiopurine 5 5-ASA, 5-aminosalicylate ▶ Fig. 1 Typical findings for each DRI score. DRI1 was defined as a normal vascular pattern in both the superficial (brown) and deep (green) vessels. DRI2 was defined as patchy or complete obliteration of the brown vessels with clear reorganization of the green vessels. DRI3 was defined as the patchy obliteration of the green vessels, and DRI4 was defined as the complete obliteration of the green vessels.
Correlation between DRI score, endoscopic score and histopathology
Next, we assessed the relationship between the DRI score and the Mayo endoscopic score. As ▶ Table 2 indicates, the DRI score was significantly correlated with the Mayo endoscopic score in analyses by both experts and non-experts (r = 0.695 -0.778; P < 0.001 in each investigator). The relationship between the DRI score and the histological grade was significantly similar for each investigator (▶ Table 3 ).
Interobserver agreement was better for the DRI score than for the Mayo endoscopic score
The κ value validating the interobserver agreement on the DRI score was moderate to excellent (mean κ value = 0.76, range 0.63 -0.88), as ▶ Table 4 a indicates. Interestingly, inter-observer agreement was even excellent among the analyses from 4 non-experts (mean κ value = 0.76, range 0.63 -0.82). However, relatively lower inter-observer agreement among the 5 investigators was observed for the Mayo endoscopic score assessments, with a mean κ value of 0.53 (▶ Table 4 b), and this agreement was significantly lower than the agreement on DRI scores (P < 0.001). Intra-observer agreement values for the Mayo endoscopic score and the DRI score were comparable (the κ values were 0.89 and 0.91, respectively).
DRI score and the prediction of prognosis in patients with clinical remission
We next assessed whether endoscopic severity assessed using DRI at baseline was associated with an increased risk of clinical recurrence among 35 patients in clinical remission. In this analysis, the highest DRI score (the most severe score) among the segments was used. Over a mean follow-up of 25.3 ± 9. ▶ (2/13), 50 % (5 /10), and 67 % (2/3), respectively. The expected time until recurrence was significantly longer in patients with lower DRI scores (▶ Fig. 3 , log-rank test, Breslow test P = 0.002). When patients were divided into a lower DRI group (DRI 1 -2) and a higher DRI group (DRI 3 -4), the mean expected time until recurrence was 33.2 months (95 % CI 30.7 -35.7) in the lower DRI group and 20.7 months (95 % CI 14.3 -27.1) in the higher DRI group.
Discussion
UC is a chronic inflammatory bowel disease characterized by blood in the stool, diarrhea, abdominal pain, and extra-intestinal symptoms. Endoscopy plays a pivotal role in the assessment of the severity of UC, and endoscopic assessment is a critical endpoint for assessing the efficacy of medications. Endoscopic remission gives an improved prognosis in patients with UC and is considered a treatment goal [11] . In patients with newly diagnosed UC who were treated with steroids, the rates of hospitalization, the need for immunosuppression therapy, and the need for colectomy were significantly higher in patients with clinical remission without mucosal healing than in those with both clinical and endoscopic remission [12] . Mucosal healing is an independent predictor of long-term outcomes from infliximab (IFX) treatment in patients with UC [13, 14] . A recent study indicated that the degree of mucosal healing after 8 weeks of IFX use was correlated with improved clinical outcomes, including a reduced incidence of colectomy [14] . In this study, the medium-term prognosis (30 weeks after the starting on IFX) was better in patients with Mayo endoscopic scores of 0 -1 than in those with Mayo endoscopic scores of 2 -3. Furthermore, significant differences between Mayo endoscopic scores of 0 and 1 that were detected 8 weeks after starting on IFX could predict clinical remission at week 30. These results suggest that endoscopy is critical for assessing the severity of inflammation and can predict medium-to long-term prognoses in UC patients after the onset of remission. Although original and modified Baron scores [15, 16] and the Mayo score for proctosigmoidoscopy [17] have been widely used and are easy for investigators to use, recent studies have demonstrated that the rate of agreement is only 27 % for endoscopic remission (Baron score 0) and 37 % for moderate activity ( Baron 2) . Inter-observer disagreement on the severity of inflammation has been reported for UC [18] . Thus, the development of new methods/techniques to assess severity is warranted. More recently, the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) and the Ulcerative Colitis Colonoscopic Index of Severity (UCCIS) were developed to solve the problem of low interobserver agreement on endoscopic scores [18 -20] . An assessment of vascular patterns including both endoscopic indices revealed excellent interobserver agreement for the vascular pattern (κ value = 0.74 -0.86), and the intraobserver agreement for the vascular pattern (κ value = 0.87) was better than that for bleeding (κ value = 0.47).
DRI was developed to easily identify blood vessels in deeper tissue. In this study, the usefulness of DRI for assessing the severity of UC was investigated by focusing on only the mucosal and submucosal vessels. Usually, the vascular pattern in a conventional colonoscopy is partially identifiable or is absent in cases of mild to moderate UC inflammation. DRI can primarily enhance the vessel pattern and the identification of deep vessels. Importantly, deep vessels can be detected even when the vascular pattern is partially visible or has disappeared using WLI. Therefore, by targeting the deep vascular pattern, DRI can be used in patients with mild to moderate endoscopic severity. Because DRI enhances the vascular pattern, inter-observer disagreement might be minimal. In fact, our study indicated that the κ values for the DRI scores between 2 investigators were better than those for the previously used endoscopic score. Furthermore, our study also indicated that the clinical prognosis is better in patients with deep vessels observed using DRI (DRI = 2) than in patients with partially visible vessels (DRI = 3). Thus, DRI is useful for predicting the middle-to long-term prognosis of UC patients. Furthermore, DRI could be used to evaluate colonic inflammation after beginning intensive medical treatment (e. g., anti-TNF agents, steroids) when the vessel pattern is absent using conventional WLI.
There are some limitations to this study. The investigators observed videos of WLI before DRI in all cases. Thus, assessment of severity based on DRI was affected by the WLI. In this study, we did not use high-definition endoscopy. However, our recent preliminary study using high-definition endoscopy indicated that the interobserver agreement on Mayo endoscopic scores was not as high (data not shown, κ value = 0.66) compared with that using DRI. Furthermore, a pathologist assessed the histopathological severity in this study, therefore, inter-observer validation of the histopathological assessment was not considered. The usefulness of DRI for UC should be assessed in a larger study. Finally, in this study, we did not assess the endoscopic usefulness of white light imaging in predicting clinical outcomes using endoscopic indices such as the Mayo score. A previous study indicated that a Mayo endoscopic score of 0 (complete endoscopic remission) predicted a better clinical outcome, and significant differences have been identified between a Mayo endoscopic score of 0 and 1 (mild endoscopic severity). However, a Mayo endoscopic score of 1 was observed in almost 70 % of the patients in our cohort. Thus, we did not confirm the significant differences that have been identified between a MES of 0 and 1 in this study. Importantly, DRI could separate patients with the same Mayo endoscopic score into groups with DRI scores of 2 or DRI scores of 3 -4.
Conclusion
In conclusion, DRI is a novel, simple tool for assessing the severity of inflammation in UC patients. The DRI score was correlated with the VAS score for the severity of colonic inflammation and exhibited a high rate of inter-observer agreement. The DRI score was closely correlated with both the endoscopic and the histological grades. The prognosis of UC can be predicted by assessing deep vessels using DRI.
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